Bringing hope through science
Oncopeptides appoints David Augustsson as Director of Corporate Affairs
Oncopeptides AB today announced that David Augustsson has been appointed Director of Corporate Affairs. As part of the company leadership team, David will be responsible for corporate communications, including strengthening the relationship with its broad investor base, and also drive the effort to reshape the corporate strategy of the company and enable the execution of it.
Annual General Meeting on May 25
On Thursday, May 25, Oncopeptides hosted its 2023 Annual General Meeting. Be sure to watch the presentation held by Oncopeptides CEO Monica Shaw, or follow this link to find more information, including the bulletin from the meeting and the filmed Q&A session.
Released
Interim report Q1 2023
”Pepaxti providing clinical benefit to patients with Multiple Myeloma”
Monica Shaw, CEO
See the Webcast
For further information, please contact:
Rolf Gulliksen
Global Head of Corporate Communications
Interim Report Q2,
August 10, 2023
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Press release -
The Swedish Economic Crime Authority terminates the investigation of Oncopeptide's Chief Scientific Officer Jakob Lindberg
Read press release
Upcoming events
Presentation of the Q1 Interim Report 2023
Oncopeptides published the report for the first quarter 2023, at 08.00 (CET) on Thursday May 4, 2023, and hosted a webcast on the same day at 09:00 (CET).
Investors, financial analysts, and media were invited to participate in the webcast and following QnA. The presentation was hosted by Monica Shaw, CEO, together with Holger Lembrér, CFO, and was held in English. The webcast was recorded.
Released
Annual Report 2022
Letter from the CEO - Providing clinical benefit to patients
For further information, please contact:
Rolf Gulliksen
Global Head of Corporate Communications
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Letter from the CEO - Providing clinical benefit to patients
Monica Shaw appointed CEO
On January 4, 2023, Oncopeptides announced that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately.
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Cultures & Values
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more